Search

Your search keyword '"Ida, Hanae"' showing total 28 results
Start Over Author "Ida, Hanae"
28 results on '"Ida, Hanae"'

2. Supplementary Figure 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Table 5 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

6. Supplementary Table 4 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Table 2 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 3 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Table 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 6 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 7 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 1 from Phase 1b/2 Study of a Liposomal Formulation of Eribulin (E7389-LF) Plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase 1b

Author

Ida, Hanae, primary, Shimizu, Toshio, primary, Nishino, Makoto, primary, Nakamura, Yoshiaki, primary, Yazaki, Shu, primary, Katsuya, Yuki, primary, Sato, Jun, primary, Koyama, Takafumi, primary, Iwasa, Satoru, primary, Sudo, Kazuki, primary, Kondo, Shunsuke, primary, Yonemori, Kan, primary, Shitara, Kohei, primary, Shiono, Satoshi, primary, Matsuoka, Daiko, primary, Yasuda, Keisuke, primary, Otake, Yohei, primary, Suzuki, Takuya, primary, Takase, Takao, primary, Takashima, Shuya, primary, Yamaguchi, Kohei, primary, Semba, Taro, primary, and Yamamoto, Noboru, primary

Published
2023
Full Text
View/download PDF

14. Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Author

Ida, Hanae, primary, Koyama, Takafumi, additional, Mizuno, Takaaki, additional, Sunami, Kuniko, additional, Kubo, Takashi, additional, Sudo, Kazuki, additional, Tao, Kayoko, additional, Hirata, Makoto, additional, Yonemori, Kan, additional, Kato, Ken, additional, Okusaka, Takuji, additional, Ohe, Yuichiro, additional, Matsui, Yoshiyuki, additional, Yamazaki, Naoya, additional, Ogawa, Chitose, additional, Kawai, Akira, additional, Narita, Yoshitaka, additional, Esaki, Minoru, additional, and Yamamoto, Noboru, additional

Published
2022
Full Text
View/download PDF

16. The outcome of watchful waiting in patients with previously treated follicular lymphoma

Author

Fujino, Takahiro, primary, Maruyama, Dai, additional, Maeshima, Akiko‐Miyagi, additional, Saito, Yo, additional, Ida, Hanae, additional, Hosoba, Rika, additional, Yuda, Sayako, additional, Makita, Shinichi, additional, Fukuhara, Suguru, additional, Munakata, Wataru, additional, Suzuki, Tatsuya, additional, Kuroda, Junya, additional, and Izutsu, Koji, additional

Published
2022
Full Text
View/download PDF

17. Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma

Author

Ida, Hanae, primary, Inamoto, Yoshihiro, additional, Fukuhara, Suguru, additional, Maeshima, Akiko Miyagi, additional, Takeda, Wataru, additional, Hirakawa, Tsuneaki, additional, Kuno, Masatomo, additional, Aoki, Jun, additional, Tanaka, Takashi, additional, Ito, Ayumu, additional, Kim, Sung‐Won, additional, Izutsu, Koji, additional, and Fukuda, Takahiro, additional

Published
2021
Full Text
View/download PDF

18. Diagnostic utility and prognostic significance of the Ki‐67 labeling index in diffuse large B‐cell lymphoma transformed from follicular lymphoma: a study of 76 patients

Author

Maeshima, Akiko Miyagi, primary, Taniguchi, Hirokazu, additional, Hori, Yoshikazu, additional, Ida, Hanae, additional, Hosoba, Rika, additional, Makita, Shinichi, additional, Fukuhara, Suguru, additional, Munakata, Wataru, additional, Suzuki, Tatsuya, additional, Maruyama, Dai, additional, and Izutsu, Koji, additional

Published
2021
Full Text
View/download PDF

20. Non–diffuse large B-cell lymphoma transformation from follicular lymphoma: a single-institution study of 19 cases

Author

Maeshima, Akiko Miyagi, primary, Taniguchi, Hirokazu, additional, Ida, Hanae, additional, Hosoba, Rika, additional, Fujino, Takahiro, additional, Saito, Yo, additional, Yuda, Sayako, additional, Makita, Shinichi, additional, Fukuhara, Suguru, additional, Munakata, Wataru, additional, Suzuki, Tatsuya, additional, Maruyama, Dai, additional, and Izutsu, Koji, additional

Published
2020
Full Text
View/download PDF

22. Acute megakaryoblastic leukaemia with t(1;22)(p13·3;q13·1)/ RBM15‐MKL1 in an adult patient following a non‐mediastinal germ cell tumour

Author

Saito, Yo, primary, Makita, Shinichi, additional, Chinen, Shotaro, additional, Kito, Momoko, additional, Fujino, Takahiro, additional, Ida, Hanae, additional, Hosoba, Rika, additional, Tanaka, Takashi, additional, Fukuhara, Suguru, additional, Munakata, Wataru, additional, Suzuki, Tatsuya, additional, Maruyama, Dai, additional, Miyagi‐Maeshima, Akiko, additional, Matsushita, Hiromichi, additional, and Izutsu, Koji, additional

Published
2020
Full Text
View/download PDF

23. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma

Author

Hosoba, Rika, primary, Makita, Shinichi, additional, Shiotsuka, Mika, additional, Kobayashi, Osamu, additional, Nakano, Kiyoko, additional, Muroya, Mimiko, additional, Okada, Naoko, additional, Suzuki, Makiko, additional, Ida, Hanae, additional, Fukuhara, Suguru, additional, Munakata, Wataru, additional, Suzuki, Tatsuya, additional, Maruyama, Dai, additional, Maeshima, Akiko Miyagi, additional, Matsushita, Hiromichi, additional, Yamamoto, Noboru, additional, Ohe, Yuichiro, additional, Iwata, Satoshi, additional, and Izutsu, Koji, additional

Published
2020
Full Text
View/download PDF

28. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.

Author

Ida H, Shimizu T, Nishino M, Nakamura Y, Yazaki S, Katsuya Y, Sato J, Koyama T, Iwasa S, Sudo K, Kondo S, Yonemori K, Shitara K, Shiono S, Matsuoka D, Yasuda K, Otake Y, Suzuki T, Takase T, Takashima S, Yamaguchi K, Semba T, and Yamamoto N

Subjects
Humans, Furans adverse effects, Ketones adverse effects, Liposomes, Nivolumab adverse effects, Neoplasms drug therapy, Vinca Alkaloids
Abstract

Purpose: To determine a recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab in patients with advanced solid tumors, and to evaluate the safety, efficacy, pharmacokinetics, and biomarker impact of this regimen., Experimental Design: Japanese patients with advanced, nonresectable, or recurrent solid tumors and no existing alternative standard/effective therapy (except nivolumab monotherapy) were assigned to either E7389-LF 1.7 mg/m 2 plus nivolumab 360 mg every 3 weeks, E7389-LF 2.1 mg/m 2 plus nivolumab 360 mg every 3 weeks, E7389-LF 1.1 mg/m 2 plus nivolumab 240 mg every 2 weeks, or E7389-LF 1.4 mg/m 2 plus nivolumab 240 mg every 2 weeks. Primary objectives were to evaluate the safety/tolerability of each dose cohort and to determine the recommended phase II dose (RP2D). Secondary/exploratory objectives, including safety [dose-limiting toxicities (DLT) and adverse events (AE)], pharmacokinetics, efficacy [including objective response rate (ORR)], and biomarker results were used in determining the RP2D., Results: Twenty-five patients were enrolled to treatment [E7389-LF 1.7 mg/mg 2 every 3 weeks ( n = 6), E7389-LF 2.1 mg/m 2 every 3 weeks ( n = 6), E7389-LF 1.1 mg/m 2 every 2 weeks ( n = 7), E7389-LF 1.4 mg/m 2 every 2 weeks ( n = 6)]. Twenty-four patients were evaluated for DLTs, of whom 3 had DLTs (1 at E7389-LF 1.7 mg/m 2 every 3 weeks, 1 at 1.1 mg/m 2 every 2 weeks, and 1 at 1.4 mg/m 2 every 2 weeks). All patients had ≥1 treatment-related treatment-emergent AE (TEAE); 68.0% had ≥1 grade 3-4 treatment-related TEAE. Changes in vasculature and IFN-related biomarkers were seen in each cohort. The overall ORR was 16%., Conclusions: E7389-LF plus nivolumab was tolerable overall; the recommended dose for future study was 2.1 mg/m 2 plus nivolumab 360 mg every 3 weeks., Significance: This phase Ib part of a phase Ib/II study assessed the tolerability and activity of a liposomal formulation of eribulin (E7389-LF) plus nivolumab in 25 patients with advanced solid tumors. The combination was tolerable overall; 4 patients had a partial response. Vasculature and immune-related biomarker levels increased, suggesting vascular remodeling., (© 2023 The Authors; Published by the American Association for Cancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results